1. Executive Summary
Oncology Market Leaders - Analyses and Outlook, 2008-2023
2. Overview of Cancer
2.1 Cancer Incidence is Rising
2.1.1 The Most Common Cancers
2.1.2 Worldwide Variation in Cancer Incidence and Mortality
2.2 Cancer Biology
2.3 Treatments for Cancer
2.3.1 Chemotherapy
2.3.1.1 Antimetabolites
2.3.1.2 Alkylating Agents
2.3.1.3 Cytotoxic antibiotics
2.3.1.4 Vinca Alkaloids
2.4 Oncology Market was the Fifth-Largest Therapeutic Area In 2007
2.5 Anti-Neoplastic Drugs Account for 50% Revenues of the Oncology Market
3. Market Forecast for the Top 10 Cancer Drugs
3.1 Top-10 Cancer Drugs Accounted for 35% Oncology Market Revenues
3.1.1 MabThera Leads Top-10 Anti-Neoplastic Drugs Market Share
3.2 MabThera
3.2.1 MabThera's Market Sales Forecast, 2008-2023
3.2.2 Development of MabThera
3.3 Herceptin
3.3.1 Herceptin Market Sales Forecast, 2008-2023
3.3.2 Development of Herceptin
3.4 Avastin
3.4.1 Avastin Market Sales Forecast, 2008-2023
3.4.2 Development of Avastin
3.5 Glivec
3.5.1 Glivec Market Sales Forecast, 2008-2023
3.5.2 Development of Glivec
3.6 Taxotere
3.6.1 Taxotere Market Sales Forecast, 2008-2023
3.6.2 Development of Taxotere
3.7 Eloxatin
3.7.1 Eloxatin Market Sales Forecast, 2008-2023
3.7.2 Development of Eloxatin
3.8 Arimidex
3.8.1 Arimidex Market Sales Forecast, 2008-2023
3.8.2 Development of Arimidex
3.9 Gemzar
3.9.1 Gemzar Market Sales Forecast, 2008-2023
3.9.2 Development of Gemzar
3.10 Caxodex
3.10.1 Casodex Market Sales Forecast, 2008-2023
3.10.2 Development Casodex
3.11 Erbitux
3.11.1 Erbitux Market Sales Forecast, 2008-2023
3.11.2 Development Erbitux
3.11 Top-10 Anti-Neoplastic Drugs High Revenue Streams Will Continue Through 2008-2023
4. Cancer Market SWOT Analysis
4.1 The World Biopharmaceutical Market Continues to Grow, But Faces Mounting Challenges
4.2 The Continuing Success of International Biopharmaceuticals Companies is Dependent Upon Important Drivers and Restraints
4.3 Companies Are Gradually Changing Their Strategic Focus to Overcome Challenges in the Worldwide Market
4.4 Reduced Efficiencies in R&D Result in Concerns Over Thinning Pipelines
4.5 Driving and Restraining Forces Acting Upon the Cancer Market
4.5.1 A SWOT Analysis for Cancer Market
4.6 Unmet Medical Needs for Cancer Remain the Major Restraint in this Market
4.7 Patient Potential to Drive Anti-Neoplastic Market
4.8 Spiralling Worldwide Rate of Cancer Will Continue to Create Revenue Opportunities for Biopharmaceutical Companies
4.9 Over 1 million Cases of Cancer Will be Diagnosed in the US in 2008
4.10 Over 3 million Cases of Cancer are Diagnosed in Europe Yearly
4.11 There is Marked Growth in Cancer in Key Emerging Markets
4.12 Sedentary Lifestyle Increases the Global Cause of Certain Cancers
4.12.1 Tobacco Smoking Leading Cause of Lung Cancer
4.12.2 Current Policy & Expansion of Smoking Bans Kick Off in Leading Markets
4.12.3 Obesity Raises the Risk of Certain Types of Cancer
4.12.4 Obesity Rates Rise Sharply In Developed Nations
4.13 The Need for New Drugs is Imperative before Cancer Attains Chronic Disease Status
4.14 Market Opportunities for New Cancer Therapies
4.14.1 Biomarkers will be Key in Early Diagnosis of Cancers
4.14.2 The Growing Investor Interest in Pharmacogenomics Holds Revenue Prospects for Cancer Drugs
4.14.3 Pharmacogenomics Holds Potential Benefits
4.15 Will Advancement in Technology Rejuvenate the Blockbuster Business Model for Anti-cancer Drugs Market Leaders?
4.16 PLM Strategies Will Be Imperative in Driving Sales of Cancer Products
4.17 Increased Combination Therapies Will Expand Revenues of Cancer Medicines
4.18 New Reformulation of Existing Products will be Significant in the Face of Rising Competition
4.19 The Cancer Vaccine Market Holds Revenue Prospects
4.19.1 Wide Use of Prophylactic Cancer Vaccines Will Rise Accordingly
4.20 Kinase-Based Anticancer Drug Screening Gain Momentum
4.21 Increasing Use of Pharmacoeconomic Evaluations Will Have an Impact on Future Revenues of Cancer Medicines
4.22 Will Major Players in Oncology Market Continue to Take More Commercial Risks
4.23 The Need for Greater R&D Efficiency Will Remain as One of the Key Priorities for Leading Companies
4.24 Lifestyle Modification will be Key in the Prevention of Cancers
4.25 Research Collaborations Will Hold Prominence if the Market is to Expand
4.26 Experts' Views on Main Issues in the Cancer Area
5. Key Players & Pipeline
5.1 Key Players in the Oncology Market Account for 70% of Global Revenues in 2007
5.1.1 Roche is the Market Leader in Cancer Therapeutics
5.2 Roche's R&D Pipeline
5.2.1 Roche Has Over 20 Phase III Studies for Oncology Underway
5.2.2 Roche has Over Six Molecules in Phase II Oncology Studies
5.2.3 Roche's Phase I Oncology Pipeline is Dominated by Small Molecule Agents
5.3 Sanofi- Aventis’ R&D Pipeline
5.3.1 Sanofi-Aventis Has a Dynamic Phase III Oncology Pipeline
5.3.2 Sanofi-Aventis' Phase II Oncology Pipeline to Largely Target Breast Cancer
5.3.3 Sanofi-Aventis’ Phase I Oncology Pipeline
5.4 Amgen's R&D Pipeline
5.4.1 Amgen Has an Impressive Phase III Oncology Pipeline
5.4.2 Amgen's Phase II Oncology Pipeline
5.4.3 Amgen's Phase I Oncology Pipeline
5.5 Novartis’ R&D Pipeline
5.5.1 Novartis Will File for New Cancer Drugs Before 2010
5.5.2 Novartis' Phase II Oncology Pipeline
5.5.3 Novartis' Phase I Oncology Pipeline
5.6 AstraZeneca’s R&D Pipeline
5.6.1 AstraZeneca's Oncology Pipeline
5.6.2 AstraZeneca has Two Candidates in Phase III Studies for NSCLC
5.6.3 AstraZeneca's Phase II Oncology Pipeline
5.6.4 AstraZeneca's Phase I Oncology Pipeline
5.7 Johnson & Johnson’s R&D Pipeline
5.7.1 J&J's Phase III Oncology Pipeline
5.7.2 J&J's Phase II Oncology Pipeline
5.7.3 J&J's Phase I Oncology Pipeline
5.8 Schering-Plough’s R&D Pipeline
5.8.1 Schering-Plough's Phase III Oncology Pipeline
5.8.2 Schering-Plough's Phase II Oncology Pipeline
5.8.3 Schering-Plough's Phase I Oncology Pipeline
5.9 Pfizer’s R&D Pipeline
5.9.1 Pfizer's Oncology Pipeline
5.9.2 Pfizer's Phase III Oncology Portfolio
5.9.3 Pfizer's Phase II Oncology Portfolio
5.9.4 Pfizer's Phase I Oncology Portfolio
5.10 Eli Lilly’s R&D Pipeline
5.10.1 Eli Lilly's Phase III Oncology Pipeline
5.10.2 Eli Lilly's Phase II Oncology Pipeline
5.10.3 Eli Lilly's Phase I Oncology Pipeline
5.11 Merck KGaA’s R&D Pipeline
5.11.1 Merck KGaA’s Phase III Oncology Pipeline
5.11.2 Merck KGaA’s Phase II Oncology Pipeline
5.11.3 Merck KGaA’s Phase I Oncology Pipeline
6. Oncology World Market Analysis
6.1 The Global Oncology Market CAGR Reaches 13% from 2004-2007
6.1.1 Global Oncology Market Sales Forecast, 2008-2023
6.2 Oncology Market Analysis in Seven Major Markets
6.2.1 US Oncology Market Analysis
6.2.2 Sales ($m) in US Oncology Market by Therapeutic Class, 2004-2007
6.2.3 US Oncology Market Sales Forecast, 2008-2023
6.3 Japan's Oncology Market Analysis
6.3.1 Sales ($m) in Japan's Oncology Market by Therapeutic Class, 2004-2007
6.3.2 Japan Oncology Market Sales Forecast, 2008-2023
6.4 The Leading EU Oncology Markets Analysis
6.4.1 France Leads the EU Anticancer Drugs Market
6.4.1.1 France's Oncology Market Analysis
6.4.1.1 France's Oncology Market Analysis
6.4.1.2 Sales ($m) in France's Oncology Market by Therapeutic Class, 2004-2007
6.4.1.3 France's Oncology Market Sales Forecast, 2008-2023
6.5 Germany's Oncology Market Analysis
6.5.1 Sales ($m) in Germany's Oncology Market by Therapeutic Class, 2004-2007
6.5.2 German Oncology Market Sales Forecast, 2008-2023
6.6 Italy's Oncology Market Analysis
6.6.1 Sales ($m) in Italy's Oncology Market by Therapeutic Class, 2004-2007
6.6.2 Italy's Oncology Market Sales Forecast, 2008-2023
6.7 Spain's Oncology Market Analysis
6.7.1 Sales ($m) in Spain's Oncology Market by Therapeutic Class, 2004-2007
6.7.2 Spain's Oncology Market Sales Forecast, 2008-2023
6.8 UK Anticancer Oncology Market
6.8.1 Sales ($m) in UK's Oncology Market by Therapeutic Class, 2004-2007
6.8.2 UK Oncology Market Sales Forecast, 2008-2023
6.9 Emerging Markets
6.9.1 China Leads the Oncology Market in Emerging Countries
6.9.2 Emerging Market & RoW Oncology Market Sales Forecast, 2008-2023
7. Most Interesting Developments
7.1 Biotech Drugs (Monoclonal Antibodies) in Cancer Treatment Rise Sharply in Leading Pipelines
7.2 R&D Trends in Kinase-Inhibitory Anticancer Drugs Widens
8. Conclusions
8.1 The Oncology Market Was the Fifth Largest Therapeutic Area in 2007
8.2 High Revenue Streams of the Top-10 Cancer Drugs Will Continue Through 2008-2023
8.3 Roche Leads the Way in R&D for Anticancer Drugs
8.4 World Market for Oncology Will Expand Significantly During 2008-2023
8.5 Most Interesting Developments
8.6 The Oncology Market Has Great Potential to Drive Year-On-Year Revenue Growth
List of Tables
Table 2.1 The Most Common Cancers Worldwide by Cancer Site
Table 2.2 Rates of Common Cancers in Developed and Developing Nations
Table 2.3 Leading Antimetabolite Drugs in Oncology
Table 2.4 Leading Alkylating Drugs in Oncology
Table 2.5 Leading Cytotoxic Antibiotics in Drugs in Oncology
Table 2.6 Leading Vinca Alkaloid Drugs in Oncology
Table 2.7 Global Therapeutic Market, 2007
Table 2.8 Global Oncology Market Revenues by Therapeutic Class, 2007
Table 3.1 Top-10 Oncology Drugs: Total Sales, 2008-2023
Table 3.2 Sales of Top 10 Anti-Neoplastic Drugs, 2007
Table 3.3 Global Sales of MabThera, 2004-2007
Table 3.4 MabThera: Total Sales, 2008-2023
Table 3.5 Global Sales of Herceptin, 2004-2007
Table 3.6 Herceptin Market Sales Forecast, 2008-2023
Table 3.7 Global Sales of Avastin, 2004-2007
Table 3.8 Avastin Market Sales Forecast, 2008-2023
Table 3.9 Global Sales of Glivec, 2004-2007
Table 3.10 Glivec Market Sales Forecast, 2008-2023
Table 3.11 Global Sales of Taxotere, 2004-2007
Table 3.12 Taxotere Market Sales Forecast, 2008-2023
Table 3.13 Global Sales of Eloxatin, 2004-2007
Table 3.14 Eloxatin Market Sales Forecast, 2008-2023
Table 3.15 Global Sales of Arimidex, 2004-2007
Table 3.16 Arimidex Market Sales Forecast 2008-2023
Table 3.17 Global Sales of Gemzar, 2004-2007
Table 3.18 Gemzar Market Sales Forecast, 2008-2023
Table 3.19 Global Sales of Casodex, 2004-2007
Table 3.20 Casodex Market Sales Forecast, 2008-2023
Table 3.21 Global Sales of Ebitux, 2004-2007
Table 3.22 Erbitux Market Sales Forecast, 2008-2023
Table 4.1 Oncology Market SWOT Analysis
Table 4.2 Cancer Cases in Leading EU Countries, 2002
Table 4.3 Cancer cases in the Key Emerging Countries, 2002
Table 4.4 Therapeutic Cancer Vaccines with Licenses or Predicted to Obtain them within the Forecast Period
Table 4.5 Prophylactic Cancer Vaccines Currently on the Market
Table 5.1 Revenues of the Top-10 Onclogy Companies, 2007
Table 5.2 Roche's Key Oncology Drugs ($m), 2007
Table 5.3 Roche's Phase III Oncology Pipeline, 2008
Table 5.4 Roche's Phase II Oncology Pipeline, 2008
Table 5.5 Roche's Phase I Oncology Pipeline, 2008
Table 5.6 Sanofi-Aventis' Key Oncology Drugs ($m), 2007
Table 5.7 Sanofi-Aventis' Phase III Oncology Pipeline, 2008
Table 5.8 Sanofi-Aventis' Phase II Oncology Pipeline, 2008
Table 5.9 Sanofi-Aventis' Phase I Oncology Pipeline, 2008
Table 5.10 Amgen's Key Oncology Drugs ($m), 2007
Table 5.11 Amgen's Phase III Oncology Pipeline, 2008
Table 5.12 Amgen's Phase II Oncology Pipeline, 2008
Table 5.13 Amgen's Phase I Oncology Pipeline, 2008
Table 5.14 Novartis' Key Oncology Drugs ($m), 2007
Table 5.15 Novartis' Phase III Oncology Pipeline, 2008
Table 5.16 Novartis' Phase II Oncology Pipeline, 2008
Table 5.17 Novartis' Phase I Oncology Pipeline, 2008
Table 5.18 AstraZeneca's Key Oncology Drugs ($m), 2007
Table 5.19 AstraZeneca's Oncology Product Extension Pipeline
Table 5.20 AstraZeneca's Phase III Oncology Pipeline, 2008
Table 5.21 AstraZeneca's Phase II Oncology Pipeline, 2008
Table 5.22 AstraZeneca's Phase I Oncology Pipeline, 2008
Table 5.23 J&J's Key Oncology Drugs ($m), 2007
Table 5.24 J&J's Phase III Oncology Pipeline, 2008
Table 5.25 J&J's Phase II Oncology Pipeline, 2008
Table 5.26 J&J's Phase I Oncology Pipeline, 2008
Table 5.27 Schering-Plough's Key Oncology Drugs ($m), 2007
Table 5.28 Schering-Plough's Phase III Oncology Pipeline, 2008
Table 5.29 Schering-Plough's Phase III Oncology Pipeline, 2008
Table 5.30 Schering-Plough's Phase III Oncology Pipeline, 2008
Table 5.31 Pfizer's Key Oncology Drugs ($m), 2007
Table 5.32 Pfizer's Phase III Oncology Pipeline, 2008
Table 5.33 Pfizer's Phase II Oncology Pipeline, 2008
Table 5.34 Pfizer's Phase I Oncology Pipeline, 2008
Table 5.35 Eli Lilly's Key Oncology Drugs ($m), 2007
Table 5.36 Eli Lilly's Phase III Oncology Pipeline, 2008
Table 5.37 Eli Lilly's Phase II Oncology Pipeline, 2008
Table 5.38 Eli Lilly's Phase II Oncology Pipeline, 2008
Table 5.39 Merck KGaA's Key Oncology Drugs ($m), 2007
Table 5.40 Merck KGaA's Phase III Oncology Pipeline, 2008
Table 5.41 Merck KGaA's Phase II Oncology Pipeline, 2008
Table 5.42 Merck KGaA's Phase I Oncology Pipeline, 2008
Table 6.1 Total Sales of All Oncology Therapeutic Classes, 2004-2007
Table 6.2 Total Sales of All Other Anti-Neoplastic Drugs, 2007
Table 6.3 Global Oncology Market: Total Sales, 2008-2023
Table 6.4 US Market Leads Sales in the Oncology Market, 2004-2007
Table 6.5 Sales ($m) in US Oncology Market by Therapeutic Class, 2004-2007
Table 6.6 US Oncology Market: Total Sales, 2008-2023
Table 6.7 Sales ($m) in Japan’s Oncology Market by Therapeutic Class, 2004-2007
Table 6.8 Japan's Oncology Market: Total Sales, 2008-2023
Table 6.9 Leading EU Oncology Market Revenues, 2004-2007
Table 6.10 Sales ($m) in France Oncology Market by Therapeutic Class, 2004-2007
Table 6.11 France’s Oncology Market: Total Sales, 2008-2023
Table 6.12 Sales ($m) in Germany’s Oncology Market by Therapeutic Class, 2004-2007
Table 6.13 Germany’s Oncology Market: Total Sales, 2008-2023
Table 6.14 Sales ($m) in Italy’s Oncology Market by Therapeutic Class, 2004-2007
Table 6.15 Italy’s Oncology Market: Total Sales, 2008-2023
Table 6.16 Sales ($m) in Spain’s Oncology Market by Therapeutic Class, 2004-2007
Table 6.17 Spain’s Oncology Market: Total Sales, 2008-2023
Table 6.18 Sales ($m) in UK’s Oncology Market by Therapeutic Class, 2004-2007
Table 6.19 UK Oncology Market: Total Sales, 2008-2023
Table 6.20 Leading Emerging Markets for Anticancer Therapeutics, 2003-2006
Table 6.21 RoW Oncology Market: Total Sales, 2008-2023
List of Figures
Figure 2.1 Incidence of and Mortality from the Most Common Cancers Worldwide
Figure 2.2 Incidence of and Mortality from the Most Common Male Cancers
Figure 2.3 Incidence of and Mortality from the Most Common Female Cancers
Figure 2.4 Rates of Cancer Incidence and Mortality in Developing Nations
Figure 2.5 Rates of Cancer Incidence and Mortality in Developed Nations
Figure 2.6 Global Therapeutic Markets, 2007
Figure 2.7 Global Therapeutic Markets, 2007
Figure 2.8 Cancer Drugs Category Sales, 2007
Figure 2.9 Cancer Drugs Category Market Share, 2007
Figure 3.1 Top-10 Oncology Drugs: Total Sales, 2008-2023
Figure 3.2 Market Share of Top-10 Anti-Neoplastic Drugs, 2007
Figure 3.3 Global Sales of MabThera, 2004-2007
Figure 3.4 MabThera: Total Sales, 2008-2023
Figure 3.5 Global Sales of Herceptin, 2004-2007
Figure 3.6 Herceptin Market Sales Forecast 2008-2023
Figure 3.7 Global Sales of Avastin, 2004-2007
Figure 3.8 Avastin Market Sales Forecast 2008-2023
Figure 3.9 Global Sales of Glivec, 2004-2007
Figure 3.10 Glivec Market Sales Forecast 2008-2023
Figure 3.11 Global Sales of Taxotere, 2004-2007
Figure 3.12 Taxotere Market Sales Forecast 2008-2023
Figure 3.13 Global Sales of Eloxatin, 2004-2007
Figure 3.14 Eloxatin Market Sales Forecast 2008-2023
Figure 3.15 Global Sales of Arimidex, 2004-2007
Figure 3.16 Arimidex Market Sales Forecast, 2008-2023
Figure 3.17 Global Sales of Gemzar, 2004-2007
Figure 3.18 Gemzar Market Sales Forecast, 2008-2023
Figure 3.19 Global Sales of Casodex, 2004-2007
Figure 3.20 Casodex Market Sales Forecast, 2008-2023
Figure 3.21 Global Sales of Ebitux, 2004-2007
Figure 3.22 Erbitux Market Sales Forecast, 2008-2023
Figure 4.1 Spectrum of Present Unmet Needs in Cancer treatment
Figure 4.2 Factors to Drive Revenue Growth in the Oncology Market
Figure 4.3 Cancer Cases in Key EU Countries, 2002
Figure 4.4 Cancer cases in the Key Emerging Countries, 2002
Figure 4.5 Cancer cases in the Two Key Emerging Countries in Europe, 2002
Figure 5.1 Revenues of the Top-10 Onclogy Companies, 2007
Figure 5.2 Market Share for Top-10 Onclogy Companies, 2007
Figure 5.3 Roche's key Oncology Drugs ($m), 2007
Figure 5.4 Roche's key Oncology Drugs Therapeutic Share, 2007
Figure 5.5 Roche Has Different Compounds in Phase III
Figure 5.6 Sanofi-Aventis' Key Oncology Drugs ($m), 2007
Figure 5.7 Sanofi-Aventis key Oncology Drugs Therapeutic Share, 2007
Figure 5.8 Amgen's Key Oncology Drugs ($m), 2007
Figure 5.9 Amgen's Key Oncology Drugs Therapeutic Share, 2007
Figure 5.10 Novartis' Key Oncology Drugs ($m), 2007
Figure 5.11 Novartis' Key Oncology Drugs Therapeutic Share, 2007
Figure 5.12 AstraZeneca's Key Oncology Drugs ($m), 2007
Figure 5.13 AstraZeneca's Key Oncology Drugs Therapeutic Share, 2007
Figure 5.14 J&J's Key Oncology Drugs ($m), 2007
Figure 5.15 J&J's Key Oncology Drugs Therapeutic Share, 2007
Figure 5.16 Schering-Plough's Key Oncology Drugs ($m), 2007
Figure 5.17 Schering-Plough's Key Oncology Drugs ($m), 2007
Figure 5.18 Pfizer's Key Oncology Drugs ($m), 2007
Figure 5.19 Pfizer's Key Oncology Drugs Therapeutic Share, 2007
Figure 5.20 Eli Lilly's Key Oncology Drugs ($m), 2007
Figure 5.21 Eli Lilly's Key Oncology Drugs Therapeutic Share, 2007
Figure 5.22 Merck KGaA's Key Oncology Drugs ($m), 2007
Figure 5.23 Merck KGaA's Key Oncology Drugs Therapeutic Share, 2007
Figure 6.1 Total Sales of All Oncology Therapeutic Classes, 2004-2007
Figure 6.2 Total Sales of All Oncology Therapeutic Classes, 2004-2007
Figure 6.3 Global Oncology Market Share, 2007
Figure 6.4 Global Oncology Market: Total Sales, 2008-2023
Figure 6.5 US Market Leads Sales inthe Oncology Market, 2004-2007
Figure 6.6 US Leads Oncology Market Share, 2007
Figure 6.7 Sales ($m) in US Oncology Market by Therapeutic Class, 2004-2007
Figure 6.8 US Oncology Market Therapeutic Classes Share, 2007
Figure 6.9 US Oncology Market: Total Sales, 2008-2023
Figure 6.10 Japan's Oncology Market Revenues, 2004-2007
Figure 6.11 Sales ($m) in Japan's Oncology Market by Therapeutic Class, 2004-2007
Figure 6.12 Japan's Oncology Market Therapeutic Classes Share, 2007
Figure 6.13 Japan's Oncology Market: Total Sales, 2008-2023
Figure 6.14 Leading EU Oncology Market Share, 2007
Figure 6.15 France's Oncology Market Revenues, 2004-2007
Figure 6.16 Sales ($m) in France Oncology Market by Therapeutic Class, 2004-2007
Figure 6.17 France's Oncology Market Therapeutic Classes Share, 2007
Figure 6.18 France Oncology Market: Total Sales, 2008-2023
Figure 6.19 Germany's Oncology Market Revenues, 2004-2007
Figure 6.20 Sales ($m) in Germany's Oncology Market by Therapeutic Class, 2004-2007
Figure 6.21 Germany's Oncology Market Therapeutic Classes Share, 2007
Figure 6.22 Germany's Oncology Market: Total Sales, 2008-2023
Figure 6.23 Italy's Oncology Market Revenues, 2004-2007
Figure 6.24 Sales ($m) in Italy's Oncology Market by Therapeutic Class, 2004-2007
Figure 6.25 Italy's Oncology Market Revenues, 2004-2007
Figure 6.26 Italy's Oncology Market: Total Sales, 2008-2023
Figure 6.27 Spain's Oncology Market Revenues, 2004-2007
Figure 6.28 Sales ($m) in Spain's Oncology Market by Therapeutic Class, 2004-2007
Figure 6.29 Spain's Oncology Market Therapeutic Classes Share, 2007
Figure 6.30 Spain's Oncology Market: Total Sales, 2008-2023
Figure 6.31 UK's Oncology Market Revenues, 2004-2007
Figure 6.32 Sales ($m) in UK's Oncology Market by Therapeutic Class, 2004-2007
Figure 6.33 UK's Oncology Market Therapeutic Classes Share, 2007
Figure 6.34 UK's Oncology Market: Total Sales, 2008-2023
Figure 6.35 Leading Emerging Markets for Anticancer Therapeutics, 2003-2006
Figure 6.36 Leading Emerging Markets Oncology Therapeutics Classes Share, 2006